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Background: Peripheral arterial disease (PAD) is a common complication in dialysis patients. Early diagnosis and
treatment are recommended. Low-density lipoprotein apheresis (LDL-A) is a potential therapy to improve PAD.
However, the mechanism has yet to be fully clarified due to lack of established quantitative methods to assess the
therapeutic effects of LDL-A treatment. Improvement of skin perfusion pressure (SPP) or ankle brachial index (ABI) is
a representative therapy goal, but clinical symptoms were not always consistent with the values of SPP/ABI.
Vascular quality of life questionnaire (VascuQOL) was proposed as a disease-specific QOL score, getting validated
recently. The possibility of VascuQOL to reflect the severity of PAD in dialysis patients and evaluate the therapeutic
effects of LDL-A has yet to be elucidated.
Methods: This is an observational study. LDL-A treatment was performed in 32 dialysis patients with PAD. They
were divided to critical limb ischemia (CLI) group (17 subjects) and non-CLI group (15 subjects) according to their
clinical manifestations. We examined the relationship of PAD severity with SPP, ABI, VascuQOL, and lipid profile
such as apoB/apoA-I ratio, malondialdehyde-modified LDL, and remnant-like particles cholesterol. Furthermore,
we evaluated these parameters successively to find out a suitable therapeutic marker just after the first LDL-A, at
tenth LDL-A, and 1 month after completion of LDL-A treatment.
Results: All of the lipid markers were higher in CLI patients, but not significantly different from those in the non-CLI
group. They decreased significantly just after LDL-A, although no changes were observed 1 month after completion of
LDL-A treatment. ABI was significantly different between the CLI and non-CLI groups, but did not improve by LDL-A
treatment. By contrast, SPP was ameliorated significantly and the peak was at tenth LDL-A. Among VascuQOL domains,
“Symptom” and “Emotional” domains were significantly different between the CLI and non-CLI groups. The average
score of VascuQOL increased successively until 1 month after completion of LDL-A treatment.
Conclusions: Several domains of VascuQOL can reflect the severity of PAD in dialysis patients. VascuQOL was a useful
marker to show the prolonged therapeutic effects of LDL-A treatment in dialysis patients with PAD, independent of SPP.
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The prevalence and incidence of peripheral arterial dis-
ease (PAD) in dialysis patients are increasing worldwide.
PAD can occur in dialysis patients with few symptoms,
often confirmed only after the patient has already exhib-
ited symptoms of critical limb ischemia (CLI) [1, 2]. Pa-
tients with CLI commonly have cardiovascular and
cerebrovascular diseases. Since survival of patients with
CLI is significantly worse than patients only with inter-
mittent claudication, early diagnosis and treatment are
quite important [3].
Generally, PAD in dialysis patients is resistant to drug
treatment, and surgical intervention is difficult. Thus,
low-density lipoprotein apheresis (LDL-A) is one of the
potential therapies for PAD to improve symptoms and
wound healings [4]. LDL-A can show “short-term” ef-
fects on lipid profile just after the therapy. However,
the quantitative evaluation methods of LDL-A “long-
term” effects at last session of one full course LDL-A
therapy and “prolonged” effects several months after
LDL-A therapy completion have not been established.
Skin perfusion pressure (SPP) and ankle brachial index
(ABI) are used to detect PAD in dialysis patients and
can be useful markers to choose LDL-A therapy re-
sponders. Especially, SPP was reported to be more ac-
curate to detect PAD in dialysis patients than ABI [5].
However, the obstruction or improvement of peripheral
circulation is not always parallel to patients’ symptom
[5, 6]. Kobayshi summarized the several mechanisms of
LDL-A [7]: (1) direct effect of lowered lipids or reduc-
tion of lipid toxicity; (2) improvement of hemorpheol-
ogy by removing fibrinogen; (3) vasodilatory effects by
an increase in VEGF/NO/bradykinin production/endothe-
lium-derived vasodilatory factors or IGF-I or a decrease in
thromboxane A2 [8, 9]; (4) reduction of circulating
vascular permeability factors; (5) anti-inflammatory
effects—reduction of oxidized LDL, P-selectin, CRP,
and ICAM-1 [10, 11]; (6) improvement of endothelial
dysfunction [12]; and (7) enhancement of corticoste-
roids or cyclosporine response by changing drug inter-
actions following lipid removal. However, the point is
that we have not found a definite quantitative marker
to suggest the long-term and prolonged therapeutic ef-
fects of LDL-A treatment on PAD in dialysis patients.
Vascular quality of life questionnaire (VascuQOL) was
presented by Morgan et al. to assess the quality of life in
PAD patients [13]. The utility of this disease-specific
questionnaire was evaluated elsewhere [14, 15]. How-
ever, to our knowledge, the utility of VascuQOL in dialy-
sis patients with PAD has yet to be fully elucidated.
Therefore, in this study, we examined the relationship
of peripheral circulation, VascuQOL, and lipid profiles
with PAD severity to pursue an effective screening
method that reflects the severity of PAD in dialysispatients. We also investigated the changes of these
quantitative parameters by LDL-A treatment to find out
a novel marker to show the long-term and prolonged ef-
fects of LDL-A treatment in dialysis patients with PAD.
Methods
Design and subjects
This study included 32 dialysis patients with PAD (24
male and 8 female patients aged 51 to 85 years) who
underwent LDL-A treatment since May 2013. Critical
limb ischemia (CLI) was defined, per “ACC/AHA Guide-
lines for the Management of Patients with PAD” [16]
and concordant TASC-II PAD guidelines [3], in patients
with Fontaine stages III and IV manifestations such as
ischemic rest pain and minor or major tissue loss of
greater than 2 weeks duration. Thus, the patients were
divided into the CLI (15 subjects) and non-CLI (17 sub-
jects with intermittent claudication, Fontaine stage II)
groups (Table 1).
LDL-A was performed once a week on the day be-
tween the first and second or second and third dialysis
session of the week, as a rule, with 10 rounds of LDL-A
set as a cycle to be provided over the course of approxi-
mately 2.5 months (Fig. 1). The mean plasma through-
put was determined to be 2900 mL for one apheresis
based on the treatment time and switchover timing of
LDL absorption column, Liposorber LA-15 (Kaneka,
Osaka, Japan). During LDL-A treatment, oral adminis-
tration of vasodilator, anti-platelet, and anti-lipidemic
drugs was performed as usual with no change, and the
conditions of dialysis remained unchanged. In addition,
our normal treatments were provided continuously for
cutaneous wounds due to PAD, nail thickening, and foot
care.
The aim of this study is to find the serological and
clinical quantitative tests which can have the relationship
with PAD severity or suggest the short-, long-term, and
prolonged effects of LDL-A treatment. Therefore, several
valuables described below were monitored repeatedly.
The non-fasting blood samples for the serological tests
were taken in the beginning of the first LDL-A (Fig. 1,
point A), just after the first LDL-A (Fig. 1, point B), the
beginning of tenth LDL-A (Fig. 1, point C), 1 month
after completion of LDL-A treatment (Fig. 1, point D).
The clinical quantitative tests were performed just be-
fore the first LDL-A (Fig. 1, point A), tenth LDL-A
(Fig. 1, point C), and 1 month after completion of LDL-
A treatment (Fig. 1, point D). B, C, and D points were
for evaluating the short- and long-term and prolonged
effects of LDL-A treatment, respectively.
As the serological tests, apoB/apoA-I ratio was deter-
mined by turbidimetric latex agglutination assays (BML,
Inc., Tokyo, Japan), reported to be a surrogate marker of
PAD [17]. In addition, malondialdehyde-modified LDL
Table 1 Clinical characteristics of the subjects enrolled
Non-CLI (n = 17) CLI (n = 15) P value
Age (years) 70.4 ± 8.0 72.0 ± 7.6 0.57
Gender (male/female) 15/2 9/6 0.08
Body mass index (kg/m2) 20.9 ± 2.6 23.4 ± 3.7 0.04
Diabetes mellitus (n, %) 11, 64.7 % 15, 100 % 0.01
Cardiovascular disease (n, %) 14, 82.4 % 14, 93.3 % 0.35
Cerebrovascular disease (n, %) 5, 29.4 % 5, 33.3 % 0.56
Duration of hemodialysis (years) 10.6 ± 9.1 9.9 ± 8.4 0.98
Laboratory data
Total cholesterol (mg/dL) 161.2 ± 41.3 178.5 ± 46.3 0.24
Triglyceride (mg/dL) 98.1 ± 78.5 127.6 ± 48.0 0.03
High-density lipoprotein cholesterol (mg/dL) 52.1 ± 15.2 52.1 ± 14.0 0.99
C-reactive protein (mg/dL) 0.34 ± 0.63 0.44 ± 0.66 0.30
Albumin (g/dL) 3.51 ± 0.32 3.43 ± 0.28 0.46
Medications
Statin (n, %) 4, 23.5 % 8, 53.3 % 0.08
Erythropoietin, darbepoetin alfa (n, %) 8, 47.1 % 7, 46.7 % 0.98
Erythropoietin, epoetin beta pegol (n, %) 5, 29.4 % 5, 33.3 % 0.81
Anti-platelet (n, %) 17, 100 % 15, 100 % N/A
Warfarin (n, %) 2, 11.8 % 4, 26.7 % 0.27
Anti-hypertensive, ARB (n, %) 2, 11.8 % 1, 6.7 % 0.55
Anti-hypertensive, Ca antagonist (n, %) 4, 23.5 % 4, 26.7 % 0.58
Anti-hypertensive, Beta blocker (n, %) 3, 17.6 % 5, 33.3 % 0.27
Anti-hypertensive, Alpha blocker (n, %) 2, 11.8 % 0, 0 % 0.27
ARB angiotensin II receptor blocker, Ca calcium, N/A not applicable
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C) were measured by an enzyme-linked immunosorbent
assay (BML, Inc., Tokyo, Japan). MDA-LDL is a marker
of coronary artery disease severity [18], which is an epi-
tope of oxidized LDL, a key actor in the initiation andA
B
C D
LDL apheresis  once a week  10 times 
A. Before the first LDL apheresis 
B. After the first LDL apheresis (Short-term effect) 
C. Tenth LDL apheresis  (Long-term effect) 
D. One month after completion of LDL apheresis treatment  
(Prolonged effect)
Fig. 1 Schedule of LDL apheresis and evaluation plan. LDL apheresis
(LDL-A) was done once a week and repeated 10 times as a cycle.
Clinical and serological evaluation in dialysis patients with peripheral
artery disease was performed before (A) and after (B) the first LDL-A,
at tenth LDL-A (C), and 1 month after completion of LDL-A treatment
(D). B, C, and D points were set to analyze the short- and long-term
and prolonged effects of LDL-A treatment, respectivelyacceleration of atherosclerosis [19]. RLP-C is atherogenic
fraction of triglyceride-rich lipoproteins, reportedly asso-
ciated with the development of PAD [20, 21]. All of the
items have not been investigated whether they can be a
marker of the prolonged effects of LDL-A treatment in
dialysis patients with PAD [9, 22, 23].
As the clinical quantitative tests, to evaluate the periph-
eral perfusion of the patients, ABI and SPP were monitored.
ABI was measured in all patients by using an ABI-form
(Colin, Tokyo, Japan) that simultaneously measured unilat-
eral brachial pressure in the arm without an arteriovenous
fistula and ankle blood pressure by using an oscillometric
method. ABI was calculated as the ratio of ankle systolic
pressure divided by brachial systolic pressure. For SPP, we
used a Laser Doppler PAD3000 (Kaneka, Osaka, Japan)
according to the method described by Okamoto et al.
[5]. Briefly, the laser Doppler skin perfusion pressure
transducer consists of a laser Doppler probe secured
within the bladder of a blood pressure cuff that con-
tains a transparent polyvinylchloride window so that
microcirculatory perfusion measurements can be made
during cuff deflation. The mean values obtained from
both legs were applied for analysis.
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In order to assess clinical symptoms quantitatively, we
used Japanese version of VascuQOL, a disease-specific
QOL score, validated previously [24, 25]. VascuQOL
contains 25 questions measuring five domains of health
status: Activity (8 questions), Symptom (4 questions),
Pain (4 questions), Emotional (7 questions), and Social
(2 questions). Each question has a 7-point response
scale. The score ranges from 1 (worst QOL) to 7 (best
QOL) [26]. Fourteen patients (82.4 %) in the non-CLI
group and 8 patients (53.3 %) in the CLI group could
complete all the questions at all of the three evaluation
points.
Statistical analysis
All values are expressed as mean ± SD. Statistical ana-
lysis was performed using SPSS for Windows version
13.0 (SPSS, Inc., Chicago, IL, USA). Baseline characteris-
tics between CLI and non-CLI patients were compared
using Student’s t test or Welch’s t test, if data were nor-
mally distributed. Non-normal data were analyzed by
Man-Whitney’s U test. F test was used for comparing the
factors of total deviation. Prevalence data were analyzed
by means of chi-square or Fisher’s exact probability test.
The changes of serological and clinical parameters in the
time course of LDL-A treatment were analyzed using
paired t test or Wilcoxon signed-ranks test, as appropriate.
Receiver operating characteristic (ROC) curve analysis
was performed to assess sensitivity or specificity. Signifi-
cance was defined by P less than 0.05.
Results
Clinical and histological characteristics
The patient background was as follows. The 32 subjects
included 26 subjects with diabetes (81.3 %), 28 with car-
diovascular disease (87.5 %), 10 with cerebrovascular dis-
ease (31.3 %), and 5 with smoking (15.6 %), showing that
many of them exhibited complications of diabetes and
vascular disease. Table 1 presents the background of the
17 subjects in the non-CLI group (53.1 %) and 15 sub-
jects in the CLI group (46.9 %). The CLI group had
higher body mass index and serum triglyceride values
with a larger percentage of DM patients than the non-
CLI group. In regard to medication, anti-platelet drug
was administered to all of the participants.
Lipid profile showed the short-term improvement
by LDL-A
First, in the beginning of the first LDL-A, all of the
apoB/apoA-I ratio, MDA-LDL, and RLP-C values were
not statistically different between the CLI and non-CLI
groups.
Next, lipid profile was followed until 1 month after
completion of LDL-A treatment. In both groups, thevalues of apoB/apoA-I ratio after the first LDL-A and
in the beginning of tenth LDL-A were significantly
lower than those in the beginning of the first LDL-A.
However, apoB/apoA-I ratio measured 1 month after
completion of LDL-A treatment was equivalent to the
level in the beginning of the first LDL-A (Fig. 2a).
MDA-LDL decreased significantly after the first LDL-
A. However, there was no significant difference between
the beginning of the first and tenth LDL-A (Fig. 2b). As
for RLP-C, in the CLI group, a significant decrease was
confirmed after the first LDL-A and in the beginning of
tenth LDL-A, compared with that in the beginning of
the first LDL-A, but no significant difference was found
1 month after completion of LDL-A treatment. In the
non-CLI group, significant decrease was detected only
just after the first LDL-A (Fig. 2c). Therefore, in this
study, lipid profile improved for a short term by LDL-
A, but they were not useful to distinguish the CLI and
non-CLI groups. Besides, LDL-A treatment did not
ameliorate the lipid markers for a long term.
Evaluation of peripheral circulation was useful to
distinguish the severity of PAD and assess the long-term
therapeutic effects of LDL-A against PAD in dialysis patients
ABI and SPP were also continuously monitored as repre-
sentative tests for peripheral circulation. Before the first
LDL-A, ABI showed a significant difference between the
CLI and non-CLI groups, while SPP did not (Fig. 3a, b).
In contrast, in the non-CLI group, SPP increased signifi-
cantly at tenth LDL-A and was sustained until 1 month
after completion of LDL-A treatment, though the values
decreased after completion of LDL-A treatment (Fig. 3b).
These findings suggest that, as reported, peripheral cir-
culation monitoring can be a clue to distinguish the se-
verity of PAD in dialysis patients and useful to evaluate
the long-term therapeutic effects of LDL-A treatment.
VascuQOL suggested the presence of CLI and reflected
the prolonged therapeutic effects of LDL-A treatment in
dialysis patients
In this study, 22 patients (68.8 %, called VascuQOL
group) could reply to all the questions required. Their
basic characteristics and the average scores of Vascu-
QOL were shown in Table 2. Before the first LDL-A, the
average score of VascuQOL was lower in the CLI group
than that in the non-CLI group, but not reaching statis-
tical significance (Fig. 4a, P = 0.07). Considering each do-
main of health status, “Symptom” and “Emotional” were
significantly lower in the CLI group than those in the
non-CLI group (Fig. 4c, e). In ROC analysis, “Symptom”
score less than 3.625 or “Emotional” score less than
3.929 indicated the presence of CLI with 75.0 % sensitiv-
ity and 85.7 % specificity. Area under the curve was


















a. ApoB/apoA-I ratio b. MDA-LDL
(mg/dL)
(mg/dL)
A B C D A B C D
A B C D
Non-CLI group
CLI group
Fig. 2 Time course of lipid profile. White square shows the non-CLI group (N = 17). Black triangle represents the CLI group (N = 15). A before the
first LDL-A. B after the first LDL-A:.C at tenth LDL-A. D 1 month after completion of LDL-A treatment. a–c At starting point (point A), all of the
apoB/apoA-I ratio, MDA-LDL, and RLP-C values were higher in the CLI group, but not statistically different between the CLI and non-CLI groups. a
apoB/apoA-I ratio improved after the first LDL apheresis (LDL-A) and in the beginning of tenth LDL-A significantly. However, it returned equivalent to
the level of starting point 1 month after completion of LDL-A treatment. b MDA-LDL decreased significantly after the first LDL-A. However, there was
no significant difference between the beginning of the first and tenth LDL-A. c As for RLP-C, in the CLI group, a significant decrease was confirmed
after the first LDL-A and in the beginning of tenth LDL-A, compared with that in the beginning of the first LDL-A, but no significant difference was
found 1 month after completion of LDL-A treatment. In the non-CLI group, a significant decrease was detected only just after the first LDL-A. All values
are expressed as mean ± SD. *P < 0.01. **P < 0.05
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until 1 month after completion of LDL-A treatment,
especially in the CLI group (Fig. 4a). In addition,
“Symptom” and “Pain” improved in both groups, and
“Activity” and “Emotional” increased significantly in
the CLI group at 1 month after completion of LDL-A
treatment (Fig. 4b–f ). Among the VascuQOL group,
SPP also improved significantly until 1 month after
completion of LDL-A treatment in the non-CLI group,
but the peak was at tenth LDL-A. Contrary to this,
ABI rather got worse, especially in the CLI group. Apo
B/apoA-I ratio, MDA-LDL, and RLP-C did not change
at 1 month after completion of LDL-A treatment in
the VascuQOL group (data not shown). These results
show that VascuQOL is one of the promising quantita-
tive methods to suggest the presence of CLI in dialysis
PAD patients and evaluate the prolonged therapeutic
effects of LDL-A treatment.Discussion
In this study, we demonstrate that VascuQOL, a disease-
specific QOL score, can be the quantitative method to
evaluate the prolonged therapeutic effects of LDL-A
treatment on PAD in dialysis patients. This question-
naire can be useful for early detection of CLI in dialysis
PAD patients. SPP was more preferable to detect the im-
provement of peripheral circulation by LDL-A treatment
compared as ABI.
VascuQOL is getting noticed as a suitable disease-
specific QOL score in intermittent claudication and
CLI. Among several disease-specific QOL instruments,
VascuQOL and its domains were reportedly most re-
sponsive to treatment [27]. The score has been used in
several prospective studies [28]. Mazai et al. showed
that VascuQOL was correlated with clinical indicators
of lower limb ischemia, such as treadmill walking dis-
tances and ABI. However, the degree of improvement
Table 2 Basic characteristics of patients who completed VascuQOL








Non-CLI 68 Male (−) 21 II 4.24 4.12 2.36
66 Male (+) 14 II 5.36 5.28 5.44
74 Male (+) 4 II 5.68 6.24 6.24
74 Male (+) 6 II 5.44 5.6 5.84
73 Male (+) 7 II 3.88 4 4
80 Male (−) 5 II 2.36 2.88 2.56
51 Male (−) 9 II 4.72 4.48 5.48
70 Male (+) 1 II 5.72 5.88 5.36
73 Male (+) 7 II 5.56 6.04 5.76
63 Male (+) 20 II 1.64 3.04 2.96
68 Female (+) 12 II 4.6 5.36 5.52
68 Male (+) 1 II 5.92 5.4 5.48
78 Male (−) 22 II 5.84 5.88 5.44
70 Male (+) 1 II 6.04 6.24 6.48
CLI 76 Male (+) 2 III 2.68 2.92 3.28
57 Male (+) 7 IV 2.64 4.6 4.16
67 Male (+) 12 III 3.36 2.52 3.64
72 Female (+) 9 III 1.92 1.8 2.84
81 Male (+) 1 III 2.24 3.04 3.72
67 Female (+) 16 III 3.36 3.48 3.64
70 Male (+) 21 IV 6.04 6.64 6.76
64 Female (+) 1 IV 5.28 4.76 5.16













a. ABI b. SPP
(mmHg)
A C D A C D
Non-CLI group
CLI group
Fig. 3 Time course of peripheral circulation. White square shows the non-CLI group (N = 17). Black triangle represents the CLI group (N = 15). A
before the first LDL-A. C at tenth LDL-A. D 1 month after completion of LDL-A treatment. a, b At starting point (point A), ABI showed a significant
difference between the CLI and non-CLI groups, while SPP did not. a ABI did not improve by LDL-A treatment. b SPP increased significantly at tenth
LDL-A and was sustained until 1 month after completion of LDL-A treatment, though the values decreased after completion of LDL-A treatment in the
non-CLI group. All values are expressed as mean ± SD. *P < 0.01. **P < 0.05

























































g. ABI h. SPP
n.p.
(mmHg)
P =  
0.07
A C D A C D A C D
A C D A C D A C D
A C D A C D
Non-CLI group
CLI group
Fig. 4 Time course of VascuQOL and its domains. Among the VascuQOL group, white square shows the non-CLI group (N = 14). Black triangle
represents the CLI group (N = 8). A before the first LDL-A. C at tenth LDL-A. D 1 month after completion of LDL-A treatment. a–f At starting
point (point A), the average score of VascuQOL was lower in the CLI group, but not reaching statistical significance (P = 0.07). “Symptom” and
“Emotional” were significantly lower in the CLI group than those in the non-CLI group. After LDL-A started, the average score of VascuQOL (a)
increased successively until 1 month after completion of LDL-A treatment, especially in the CLI group. “Symptom” (c) and “Pain” (d) improved
in both groups, and “Activity” (b) and “Emotional” (e) increased significantly in the CLI group at 1 month after completion of LDL-A treatment.
g, h Among the VascuQOL group, SPP (h) improved significantly until 1 month after completion of LDL-A treatment in the non-CLI group, but
the peak was at tenth LDL-A. Contrary to this, ABI (g) rather got worse, especially in the CLI group. All values are expressed as mean ± SD.
*P < 0.01. **P < 0.05
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reflected in these scores. These findings support the
use of composite outcome measures with independent
assessment of QOL as an independent outcome meas-
ure in intervention studies in these patients [29]. How-
ever, to our knowledge, this questionnaire has not been
applied to assess LDL-A treatment effects on PAD in
dialysis patients. This is the first report to suggest its
utility as a unique and independent method to quantify
the therapeutic results of LDL-A treatment against
PAD in dialysis patients. VascuQOL could detect theprolonged effects of LDL-A treatment and the time
course of the score was not parallel to SPP, one of the
representative clinical indicators. SPP could indicate
the LDL-A effects at the last LDL-A, but not excellent
to estimate the prolonged improvement by LDL-A
treatment. We believe that quantitative evaluation
using the combination of VascuQOL and SPP can be a
novel marker in order to clarify the precise mechanism
of LDL-A treatment.
As described in the “Background” section, early diag-
nosis of PAD is important to prevent the disease
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that SPP set at 50 mm Hg was more accurate than ABI
to detect PAD, with sensitivity of 84.9 % and specificity
of 76.9 % [5]. In our study, SPP was not significantly dif-
ferent between the CLI group and non-CLI group. We
do need the other screening method that reflects the se-
verity of PAD in dialysis patients. Nguern et al. reported
that patients with CLI have a low QOL at baseline [30].
VascuQOL consists of five domains of health status. In
our study, among the domains, “Symptom” and “Emo-
tional” showed significant differences between the CLI
group and non-CLI group. ROC analysis showed that
cutoff scores of “Symptom” or “Emotional” had 75.0 %
sensitivity and 85.7 % specificity, even though only with
moderate accuracy. These results suggest that Vascu-
QOL can be a potential quantitative method to suspect
the existence of CLI in dialysis PAD patients. One more
advantage of VascuQOL over SPP is easy for every
health professional to administer, score, and analyze
without using any specific measuring machine [26].
There are still few reports to clarify the relationship
between PAD and lipid markers such as apoB/apoA-I ra-
tio, MDA-LDL, and RLP-C in dialysis patients. In this
study, we examined the correlation of these atheroscler-
otic risk markers with PAD severity. Then, they did not
show any difference between the non-CLI and CLI
groups. However, all of the atherosclerotic risk markers
were higher in the CLI group at the first LDL-A and
1 month after completion of LDL-A treatment. There-
fore, apoB/apoA-I ratio, MDA-LDL, and RLP-C can be
related to the development of PAD and the target values
of preventive drug therapy for PAD in dialysis patients.
Although the present study demonstrated the possi-
bility of VascuQOL to evaluate LDL-A treatment in
dialysis patients with PAD, there are several major limi-
tations. The main problem of this study is the lack of
criterial parameter to evaluate the usefulness of Vascu-
QOL. We have assessed VascuQOL on a speculation
that it is taken for granted that PAD improve certainly
after treatment of LDL-A. In order to assess the useful-
ness of VascuQOL for the estimation of the prolonged
improvement by LDL-A treatment, it is essential to
compare VascuQOL with a parameter which is well
known and correlate with PAD state precisely. How-
ever, there are not a few patients whose symptom is
relieved for a longer period without significant im-
provement of microcirculation parameters, maybe be-
cause of a number of complex local microcirculatory
responses, which may contribute to rest pain and
trophic changes [3, 9]. Most of the prospective study to
assess the treatment of PAD select some parameters
among the blood flow measurement (SPP, ABI), exer-
cise ability (walking distance), and QOL survey (Vascu-
QOL, SF-36) as main outcomes [28, 29]. It means thatthere is no gold standard method to evaluate the re-
sponse to the therapy. We will need total assessment of
several methods such as SPP and VascuQOL in order
to evaluate the response to the therapy. Second, the
present study includes a small sample size that could
cause unknown source of bias in the findings. Third,
the compliance to answer VascuQOL was poor. In this
study, only patients who completed all the questions at
all of the three evaluation points were analyzed. Vascu-
QOL consists of simple questionnaire, but the number
of questions might be large for older patients. Actually,
a trial to reduce the number of questions has been already
performed [26]. Several domains such as “Pain”, “Symp-
tom,” and “Emotional” can be selected and assessed in the
future studies to achieve better compliance.
Conclusions
We administered LDL-A treatment to 32 dialysis pa-
tients with PAD. At starting point, lipid-related arterio-
sclerosis markers such as apoB/apoA-I ratio, MDA-LDL,
and RLP-C in the CLI group were higher than those in
the non-CLI group, but not reaching a significant differ-
ence. Not only ABI, but “Symptom” and “Emotional” do-
mains of VascuQOL were significantly higher in the CLI
group. After LDL-A started, the improvement of lipid
profile could not be maintained until 1 month after
completion of LDL-A treatment. However, SPP im-
proved especially at tenth LDL-A. VascuQOL improved
successively until 1 month after completion of LDL-A
treatment. In summary, “Symptom” and “Emotional” do-
mains of VascuQOL can be applicable to know the se-
verity of PAD in dialysis patients. LDL-A treatment
induced the improvement of SPP for a long term, which
caused the continuous increase of VascuQOL in dialysis
patients with PAD until 1 month after completion of
LDL-A treatment without changing lipid markers. Vas-
cuQOL was useful to analyze the prolonged effects of
LDL-A treatment.
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